Does a single dose of XBD173 change blood sugar in healthy adults?
Official title: An Experimental Medicine Study to Investigate the Role of the 18 kiloDalton Translocator Protein in Glucose Metabolism
Run by Imperial College London · NCT07682233 · Data updated 2026-11-12
A single dose of XBD173 is being tested in healthy adults to see if it affects fasting and after-glucose-drink blood sugar levels compared with a placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Imperial College London Academic / other |
| Drugs / interventions | Crizotinib, Imatinib, Nilotinib |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | March 27, 2026 |
| Main results expected | September 1, 2028 |
| Study ends | September 1, 2028 |
| Registry record updated | July 2, 2026 |
| Trial ID | NCT07682233 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 18 to 75 without diabetes and meeting contraception and health criteria.
✕Probably not a fit
Individuals with diabetes, significant liver or kidney dysfunction, or abnormal blood tests may not experience a glucose-related benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 interventional study investigates whether activating the mitochondrial TSPO receptor with XBD173 alters glucose metabolism in healthy volunteers aged 18 to 75. The trial uses a randomized, placebo-controlled design with a single oral dose and compares fasting glucose and glucose challenge responses. Participants undergo screening, then four study visits after overnight fasting: two with a glucose drink and two without. Safety and eligibility criteria exclude individuals with diabetes or notable organ dysfunction, and contraception requirements are specified for sexually active participants.
Why it matters
Potential benefit: If successful, the study could reveal whether TSPO activation influences glucose metabolism and inform future diabetes-related research.
How similar studies have gone: Prior research with TSPO-targeted approaches has shown mixed or exploratory results; this study tests a novel single-dose approach in healthy volunteers.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
* Aged 18-75 years old
* A female subject is eligible to participate if she is a) of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea or b) of childbearing potential but not pregnant (as determined by urinary pregnancy test on screening and on each study day) and willing to use one of the contraception methods.
* Male subject must agree to use one of the contraception methods.
* No history of diabetes.
Exclusion Criteria:
* Clinically meaningful abnormalities in routine bloods including:
* eGFR \< 60ml/min
* Elevation of liver enzymes/bilirubin
* Prolonged prothrombin time
* Thrombocytopenia
* Use of the following medications or therapies:
* P450 CY3A4 inhibitors
* Potent: Boceprevir, Clarithromycin, Cobicistat, Idelalisib, Itraconazole, Ketoconazole, Nelfinavir, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazoleb
* Moderate: Aprepitant, Conivaptan, Crizotinib, Diltiazem, Dronedarone, Erythromycin, Fluconazole, Imatinib, Isavuconazole, Nefazodone, Netupitant, Nilotinib, Posaconazolee, Tofisopam, Verapamil
* Unclassified: Delavirdine
* P450 CY3A4 inducers
* Potent: Carbamazepine, Enzalutamide, Fosphenytoin, Mitotane, Phenytoin, Rifampicin
* Moderate; Bosentan, Efavirenz, St John's wort
* Unclassified; Barbiturates, Nevirapine, Primidone, Rifabutin, Rifapentine
* oral contraceptives
* oral anticoagulants or antiplatelet agents other than low dose aspirin
* levothyroxine
* Currently breastfeeding.
* Any clinical significant medical conditions that in the opinion of the investigator would compromise subjects' safety or compliance with study procedures.
* History of any clinical condition which in the opinion of the principal investigator would compromise the scientific integrity of the study, such as some chronic systemic diseases affecting blood, liver or kidneys or endocrine system.
* Unwillingness or inability to follow the procedures outlined in the protocol.
* Subject is mentally or legally incapacitated.
* Contraindication to XBD173 use:
* Hypersensitivity to the active substance or to any of the excipients
Where it's running
-
NIHR Trust Imperial Clinical Research Facility
London, United Kingdom Recruiting
Study contacts
- Study coordinator: David R Owen
- Email: d.owen@imperial.ac.uk
- Phone: +44 07801140800
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prebiotic formulation and its effects on gut microbiota and body composition in adults
A prebiotic supplement (PI-YSP-0111) is being tested in healthy adults to see if 8 weeks of use can favorably change gut bacteria and body composition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.